MCID: PYR010
MIFTS: 52

Peyronie's Disease

Categories: Rare diseases, Reproductive diseases

Aliases & Classifications for Peyronie's Disease

MalaCards integrated aliases for Peyronie's Disease:

Name: Peyronie's Disease 39 12 14
Peyronie Disease 12 50 52 69
Balanitis Xerotica Obliterans 69
Induratio Penis Plastica 12
Peyronie's Fibromatosis 12
Peyronies Disease 39
Penile Induration 42
Penile Curvature 50

Classifications:



External Ids:

Disease Ontology 12 DOID:8616
ICD10 33 N48.6
ICD9CM 35 607.85
MeSH 42 D010411
NCIt 47 C3316
SNOMED-CT via HPO 65 287085006 42030000
UMLS 69 C0030848

Summaries for Peyronie's Disease

NIH Rare Diseases : 50 peyronie disease is a connective tissue disorder characterized by a plaque, or hard lump, that forms within the penis. affected individuals may experience painful, curved erections which can make make normal sexual intercourse impossible. symptoms may appear suddenly or develop gradually. while the painful erections for most men resolve over time, the scar tissue and curvature may remain. some cases appear to resolve spontaneously. the exact cause of peyronie's disease is not known. last updated: 11/23/2011

MalaCards based summary : Peyronie's Disease, also known as peyronie disease, is related to ledderhose disease and rectum neuroendocrine neoplasm, and has symptoms including abnormality of the skeletal system, abnormality of the genitourinary system and penile edema. An important gene associated with Peyronie's Disease is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Acetylcholine and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include small intestine, bone and prostate, and related phenotypes are cellular and craniofacial

Wikipedia : 72 Peyronie\'s disease or Peyronie disease (/peɪroʊˈniː/), also known as induratio penis plastica (IPP) or... more...

Related Diseases for Peyronie's Disease

Diseases related to Peyronie's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 29)
id Related Disease Score Top Affiliating Genes
1 ledderhose disease 10.8
2 rectum neuroendocrine neoplasm 10.4 IFNA2 TGFB1
3 tgfbr2-related thoracic aortic aneurysms and aortic dissections 10.3 TGFB2 TGFB3
4 hypospadias 10.3
5 acromicric dysplasia 10.3 TGFB1 TGFB2
6 loeys-dietz syndrome 4 10.2 TGFB2 TGFB3
7 clear cell adenocarcinoma 10.2 TGFB2 TGFB3
8 ohdo syndrome, maat-kievit-brunner type 10.2 DCN TGFB1
9 congenital methemoglobinemia 10.1 SMAD3 TGFB1 TGFB3
10 vacterl association 10.0 PDE5A TGFB1
11 strawberry gallbladder 10.0 TGFB1 TGFB2 TGFB3
12 rheumatic myocarditis 10.0 DCN SMAD3 TGFB1
13 gnas hyperfunction 10.0 SMAD3 TGFB2 TGFB3
14 bleeding disorder, platelet-type, 21 9.9 SMAD3 TGFB2
15 epidemic typhus 9.9 SMAD3 TGFB2 TGFB3
16 west syndrome 9.9 DCN TGFB2
17 pyridoxine deficiency 9.8 SMAD7 TGFB1
18 pulmonary edema 9.8
19 priapism 9.8
20 urticaria 9.7 IFNA2 PDE5A SMAD3 TGFB1
21 idiopathic corneal edema 9.7 TGFB2 TGFB3
22 pulmonary valve insufficiency 9.7 SMAD3 SMAD7 TGFB1
23 perrault syndrome 9.6 SMAD3 SMAD7 TGFB1
24 acromesomelic dysplasia 9.6 SMAD3 SMAD7 TGFB3
25 microscopic colitis 9.5 NOS2 SMAD3 SMAD7
26 keratopathy 9.3 SMAD3 SMAD7 TGFB1 TGFB3
27 nephrotic syndrome, idiopathic, steroid-resistant 9.2 DCN SMAD3 SMAD7 TGFB1
28 colorectal cancer 8.0 IFNA2 NOS2 SMAD3 SMAD7 TGFB1 TGFB2
29 twin-to-twin transfusion syndrome 6.5 ACTG2 DCN IFNA2 NOS2 PDE5A SMAD3

Comorbidity relations with Peyronie's Disease via Phenotypic Disease Network (PDN):


Bladder Neck Obstruction Prostatic Hypertrophy
Urethral Stricture

Graphical network of the top 20 diseases related to Peyronie's Disease:



Diseases related to Peyronie's Disease

Symptoms & Phenotypes for Peyronie's Disease

Human phenotypes related to Peyronie's Disease:

32
id Description HPO Frequency HPO Source Accession
1 abnormality of the skeletal system 32 HP:0000924
2 abnormality of the genitourinary system 32 HP:0000119

UMLS symptoms related to Peyronie's Disease:


penile edema

MGI Mouse Phenotypes related to Peyronie's Disease:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.04 DCN NOS2 SMAD3 SMAD7 TGFB1 TGFB2
2 craniofacial MP:0005382 10.02 DCN NOS2 SMAD3 SMAD7 TGFB1 TGFB2
3 digestive/alimentary MP:0005381 10 SMAD7 TGFB1 TGFB2 TGFB3 DCN NOS2
4 hematopoietic system MP:0005397 9.95 DCN NOS2 SMAD3 SMAD7 TGFB1 TGFB2
5 endocrine/exocrine gland MP:0005379 9.91 DCN NOS2 SMAD3 SMAD7 TGFB1 TGFB2
6 immune system MP:0005387 9.91 DCN NOS2 SMAD3 SMAD7 TGFB1 TGFB2
7 reproductive system MP:0005389 9.73 DCN NOS2 SMAD3 SMAD7 TGFB1 TGFB2
8 renal/urinary system MP:0005367 9.72 DCN NOS2 SMAD3 TGFB1 TGFB2
9 respiratory system MP:0005388 9.55 DCN NOS2 TGFB1 TGFB2 TGFB3
10 skeleton MP:0005390 9.43 TGFB3 DCN NOS2 SMAD3 TGFB1 TGFB2
11 vision/eye MP:0005391 9.1 DCN NOS2 SMAD3 TGFB1 TGFB2 TGFB3

Drugs & Therapeutics for Peyronie's Disease

Drugs for Peyronie's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 2 51-84-3 187
2
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
3 abobotulinumtoxinA Phase 2
4 Cholinergic Agents Phase 2
5 Neuromuscular Agents Phase 2
6 Neurotransmitter Agents Phase 2
7 onabotulinumtoxinA Phase 2
8 Peripheral Nervous System Agents Phase 2
9 Pharmaceutical Solutions Phase 2
10 Botulinum Toxins Phase 2
11 Botulinum Toxins, Type A Phase 2
12 Central Nervous System Depressants Phase 2
13 Sodium Channel Blockers Phase 2
14 Anesthetics Phase 2
15 Anesthetics, Local Phase 2
16 Diuretics, Potassium Sparing Phase 2
17 Anti-Arrhythmia Agents Phase 2
18
Testosterone Approved, Investigational Phase 1 58-22-0 6013
19
Methyltestosterone Approved Phase 1 58-18-4 6010
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2
21 Tocopherol Approved, Nutraceutical Phase 1
22
Ergocalciferol Approved, Nutraceutical Phase 1 50-14-6 5280793
23
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1 59-02-9 14985
24 Testosterone undecanoate Phase 1
25
Testosterone enanthate Phase 1 315-37-7 9416
26 Micronutrients Phase 1
27 Anabolic Agents Phase 1
28 Testosterone 17 beta-cypionate Phase 1
29 Androgens Phase 1
30 Tocopherols Phase 1
31 Tocotrienols Phase 1
32 Hormone Antagonists Phase 1
33 Trace Elements Phase 1
34 Hormones Phase 1
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1
36 Ergocalciferols Phase 1
37 Vitamins Phase 1
38 Protective Agents Phase 1
39 Bone Density Conservation Agents Phase 1
40 Antineoplastic Agents, Hormonal Phase 1
41 Antioxidants Phase 1
42 Tocotrienol Investigational, Nutraceutical Phase 1 6829-55-6
43 Vitamin D2 Nutraceutical Phase 1
44 Calciferol Nutraceutical Phase 1
45 Phosphodiesterase 5 Inhibitors

Interventional clinical trials:

(show all 17)

id Name Status NCT ID Phase Drugs
1 Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease Active, not recruiting NCT02298829 Phase 4 Subjects Previously Treated with AA4500
2 A Study of AA4500 in Men With Peyronie's Disease Completed NCT01243411 Phase 3
3 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01685437 Phase 3
4 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221597 Phase 3
5 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221623 Phase 3
6 An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease Completed NCT02267460 Phase 3
7 Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) Unknown status NCT01184586 Phase 2
8 The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Completed NCT00755222 Phase 2
9 Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease Completed NCT01430169 Phase 2
10 H-22411: BOTOX® for Peyronie's Disease Recruiting NCT00812838 Phase 2 100 units of Botulinum Toxin Type A
11 Clostridium Histolyticum Collagenase Injection for Urethral Disease Not yet recruiting NCT02948842 Phase 2 Clostridium Histolyticum Collagenase;Lidocaine
12 Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Unknown status NCT01578473 Phase 1 Vitamin D2;Vitamin E;Testosterone Pellets
13 Peyronie's Disease Treatment Protocol Completed NCT02072018 Phase 1 H-100;Placebo
14 Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD Completed NCT02395029 Phase 1
15 Management of Peyronie's Disease With Adipose Tissue Stem Cell Unknown status NCT02414308 Adipose tissue stem cell injection
16 Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830
17 Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy Completed NCT00800813

Search NIH Clinical Center for Peyronie's Disease

Cochrane evidence based reviews: penile induration

Genetic Tests for Peyronie's Disease

Anatomical Context for Peyronie's Disease

MalaCards organs/tissues related to Peyronie's Disease:

39
Small Intestine, Bone, Prostate, Endothelial, Testes, Monocytes, Eye

Publications for Peyronie's Disease

Articles related to Peyronie's Disease:

(show top 50) (show all 645)
id Title Authors Year
1
Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease. ( 28554517 )
2017
2
Role of interleukin-6 and pentraxin 3 as an early marker in Peyronie's disease. ( 28359407 )
2017
3
Peyronie's disease - Watch out for the bend. ( 28892596 )
2017
4
Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease-A Review of the Literature and a New Modified Protocol. ( 28874327 )
2017
5
Extracellular matrix alterations in the Peyronie's disease. ( 28721300 )
2017
6
Prevalence of Peyronie's Disease-Like Symptoms in Men Presenting With Dupuytren Contractures. ( 28676223 )
2017
7
Surgical outcomes from limiting the use of nonabsorbable suture in tunica albuginea plication for Peyronie's disease. ( 28835714 )
2017
8
Successful Treatment of Residual Curvature in Peyronie's Disease in Men Previously Treated with Intralesional Collagenase Clostridium Histolyticum. ( 28886994 )
2017
9
Changes in the Effects of Peyronie's Disease After Treatment With Collagenase Clostridium histolyticum: Male Patients and Their Female Partners. ( 28395998 )
2017
10
Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol. ( 28612401 )
2017
11
Collagenase clostridium hystolyticum in the management of Peyronie's disease. ( 28540240 )
2017
12
Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application. ( 28791261 )
2017
13
Recent Pathophysiological Aspects of Peyronie's Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment-Literature Review. ( 28744308 )
2017
14
Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study. ( 28718527 )
2017
15
Response and Rebuttal to Letter to the Editor: Evidence-Based Management Guidelines on Peyronie's Disease. ( 28065353 )
2017
16
Serious complications of collagenase clostridium histiolyticum injection for Peyronie's disease: more than meets the eye! ( 28540246 )
2017
17
Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute-Phase Peyronie's Disease. ( 28874331 )
2017
18
Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: Review of a Minimally Invasive Treatment Option. ( 28879693 )
2017
19
Sexual dysfunction: Shortened CCH treatment for Peyronie's disease. ( 28675171 )
2017
20
Effect of Penile Traction and Vacuum Erectile Device for Peyronie's Disease in an Animal Model. ( 28923308 )
2017
21
Does Transfer Capacitive Resistive Energy Has a Therapeutic Effect on Peyronie's Disease? Randomized, Single-Blind, Sham-Controlled Study on 96 Patients: Fast Pain Relief. ( 28482350 )
2017
22
Moving from Consensus- to Evidence-Based Clinical Practice Guidelines for Peyronie's Disease. ( 28065352 )
2017
23
Three-Dimensional Photography for Quantitative Assessment of Penile Volume-Loss Deformities in Peyronie's Disease. ( 28460995 )
2017
24
Con: does shockwave therapy have a place in the treatment of Peyronie's disease? ( 27298785 )
2016
25
A review of surgical strategies for penile prosthesis implantation in patients with Peyronie's disease. ( 27298781 )
2016
26
Impact of Number of Cycles of Collagenase Clostridium Histolyticum on Outcomes in Patients with Peyronie's Disease. ( 27816605 )
2016
27
Peyronie's Disease and Injectable Collagenase Clostridium Histolyticum: Safety, Efficacy and Improvements in Subjective Symptoms. ( 27211926 )
2016
28
Buccal mucosa is a promising graft in Peyronie's disease surgery. Our experience and a brief literature review on autologous grafting materials. ( 27377087 )
2016
29
A review of the epidemiology and treatment of Peyronie's disease. ( 27200305 )
2016
30
Review of Management Options for Patients With Atypical Peyronie's Disease. ( 27544298 )
2016
31
Contemporary Review of Treatment Options for Peyronie's Disease. ( 26898900 )
2016
32
Re: Outcomes of Surgical Management of Men with Peyronie's Disease with Hourglass Deformity. ( 27628824 )
2016
33
Intralesional Injection of Hyaluronic Acid in Patients Affected With Peyronie's Disease: Preliminary Results From a Prospective, Multicenter, Pilot Study. ( 26984291 )
2016
34
The Efficacy of Medical Treatment of Peyronie's Disease: Potassium Para-Aminobenzoate Monotherapy vs. Combination Therapy with Tamoxifen, L-Carnitine, and Phosphodiesterase Type 5 Inhibitor. ( 27169128 )
2016
35
Re: The Prevalence of Peyronie's Disease in the United States: AA Population-Based Study. ( 27628825 )
2016
36
The Prevalence of Peyronie's Disease in the United States: A Population-Based Study. ( 26907743 )
2016
37
--- ---Recent advances in managing Peyronie's disease. ( 27746896 )
2016
38
Peyronie's Disease: Intralesional Therapy and Surgical Intervention. ( 27432377 )
2016
39
The Outcome of Multiple Slit on Plaque with Plication Technique for the Treatment of Peyronie's Disease. ( 27169125 )
2016
40
Collagenase Clostridium Histolyticum for the Treatment of Peyronie's Disease: A 'Real World' Clinical Perspective. ( 27770352 )
2016
41
Grafting techniques for Peyronie's disease. ( 27298780 )
2016
42
Re: Comparative Analysis of Tunical Plication vs. Intralesional Injection Therapy for Ventral Peyronie's Disease. ( 27186764 )
2016
43
Nonsurgical treatment options in Peyronie's Disease: 2016 update. ( 27909612 )
2016
44
Lengthening strategies for Peyronie's disease. ( 27298782 )
2016
45
Increased aquaporin 1 expression in the tunica albuginea of Peyronie's disease patients: an in vivo pilot study. ( 26972451 )
2016
46
Pro: does shockwave therapy have a place in the treatment of Peyronie's disease? ( 27298784 )
2016
47
The Therapeutic Effects of Intracavernosal Plaque Excision in Peyronie's Disease: A None Grafting or Tunical Excising Procedure. ( 27308243 )
2016
48
Satisfaction of patients with Peyronie's disease after plaque surgery and bovine pericardium graft. ( 27468940 )
2016
49
Re: Topical Treatment for Acute Phase Peyronie's Disease Utilizing a New Gel, H-100: A Randomized, Prospective, Placebo-Controlled Pilot Study. ( 27186765 )
2016
50
Research highlights on stem cell therapy for the treatment of Peyronie's disease. ( 27298783 )
2016

Variations for Peyronie's Disease

Expression for Peyronie's Disease

Search GEO for disease gene expression data for Peyronie's Disease.

Pathways for Peyronie's Disease

Pathways related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.52 IFNA2 NOS2 SMAD3 TGFB1 TGFB2 TGFB3
2
Show member pathways
13.41 IFNA2 SMAD3 SMAD7 TGFB1 TGFB2 TGFB3
3
Show member pathways
13.21 IFNA2 NOS2 PDE5A TGFB1 TGFB2 TGFB3
4
Show member pathways
13.17 ACTG2 SMAD3 TGFB1 TGFB2 TGFB3
5
Show member pathways
12.83 ACTG2 NOS2 TGFB1 TGFB2 TGFB3
6
Show member pathways
12.75 ACTG2 TGFB1 TGFB2 TGFB3
7
Show member pathways
12.73 IFNA2 NOS2 SMAD3 TGFB1 TGFB2 TGFB3
8
Show member pathways
12.65 DCN TGFB1 TGFB2 TGFB3
9 12.59 NOS2 SMAD3 TGFB1 TGFB2 TGFB3
10
Show member pathways
12.52 SMAD3 TGFB1 TGFB2 TGFB3
11
Show member pathways
12.42 SMAD3 TGFB1 TGFB2 TGFB3
12 12.36 SMAD3 TGFB1 TGFB2 TGFB3
13 12.3 SMAD3 TGFB1 TGFB2 TGFB3
14
Show member pathways
12.24 TGFB1 TGFB2 TGFB3
15 12.2 DCN TGFB1 TGFB2
16
Show member pathways
12.19 SMAD3 SMAD7 TGFB1
17
Show member pathways
12.19 NOS2 TGFB1 TGFB2 TGFB3
18 12.17 SMAD3 TGFB1 TGFB2 TGFB3
19
Show member pathways
12.12 SMAD3 TGFB1 TGFB2
20 12.08 IFNA2 NOS2 TGFB1 TGFB2 TGFB3
21
Show member pathways
12.03 SMAD3 TGFB1 TGFB2 TGFB3
22 11.99 SMAD3 SMAD7 TGFB1
23 11.94 NOS2 SMAD3 TGFB1 TGFB2 TGFB3
24 11.88 ACTG2 SMAD3 TGFB1 TGFB2 TGFB3
25 11.86 SMAD3 TGFB1 TGFB2 TGFB3
26
Show member pathways
11.85 SMAD3 TGFB1 TGFB2 TGFB3
27 11.84 NOS2 TGFB1 TGFB2 TGFB3
28 11.84 SMAD3 SMAD7 TGFB1 TGFB2 TGFB3
29 11.83 DCN TGFB1 TGFB2 TGFB3
30 11.81 TGFB1 TGFB2 TGFB3
31 11.79 TGFB1 TGFB2 TGFB3
32
Show member pathways
11.71 TGFB1 TGFB2 TGFB3
33 11.7 SMAD3 SMAD7 TGFB1
34
Show member pathways
11.68 SMAD3 SMAD7 TGFB1
35 11.64 NOS2 TGFB1 TGFB2 TGFB3
36 11.62 TGFB1 TGFB2 TGFB3
37 11.58 SMAD3 SMAD7 TGFB1
38
Show member pathways
11.57 SMAD3 TGFB1 TGFB2 TGFB3
39 11.53 TGFB1 TGFB2 TGFB3
40 11.51 NOS2 SMAD3 TGFB1
41 11.51 DCN TGFB1 TGFB2 TGFB3
42 11.49 TGFB1 TGFB2 TGFB3
43
Show member pathways
11.38 TGFB1 TGFB2 TGFB3
44 11.38 SMAD3 SMAD7 TGFB1 TGFB3
45 11.35 SMAD3 SMAD7 TGFB1 TGFB2 TGFB3
46
Show member pathways
11.34 NOS2 PDE5A
47 11.29 NOS2 TGFB3
48 11.28 IFNA2 NOS2
49
Show member pathways
11.19 SMAD7 TGFB1 TGFB3
50 11.12 TGFB1 TGFB3

GO Terms for Peyronie's Disease

Cellular components related to Peyronie's Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.63 ACTG2 DCN IFNA2 TGFB1 TGFB2 TGFB3
2 extracellular matrix GO:0031012 9.26 DCN TGFB1 TGFB2 TGFB3
3 platelet alpha granule lumen GO:0031093 8.8 TGFB1 TGFB2 TGFB3

Biological processes related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.99 SMAD3 TGFB1 TGFB2 TGFB3
2 negative regulation of gene expression GO:0010629 9.89 IFNA2 NOS2 TGFB1
3 aging GO:0007568 9.88 DCN TGFB1 TGFB3
4 cell cycle arrest GO:0007050 9.87 SMAD3 TGFB1 TGFB2
5 platelet degranulation GO:0002576 9.86 TGFB1 TGFB2 TGFB3
6 negative regulation of cell growth GO:0030308 9.85 SMAD3 TGFB1 TGFB2
7 cellular response to transforming growth factor beta stimulus GO:0071560 9.83 SMAD3 SMAD7 TGFB1
8 cell growth GO:0016049 9.83 TGFB1 TGFB2 TGFB3
9 inner ear development GO:0048839 9.82 TGFB1 TGFB2 TGFB3
10 BMP signaling pathway GO:0030509 9.81 SMAD7 TGFB1 TGFB2 TGFB3
11 response to hypoxia GO:0001666 9.8 NOS2 SMAD3 TGFB1 TGFB2 TGFB3
12 cell development GO:0048468 9.79 TGFB1 TGFB2 TGFB3
13 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.79 TGFB1 TGFB2 TGFB3
14 positive regulation of cell division GO:0051781 9.78 TGFB1 TGFB2 TGFB3
15 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.78 SMAD3 SMAD7 TGFB1 TGFB3
16 ureteric bud development GO:0001657 9.77 SMAD3 SMAD7 TGFB1
17 extrinsic apoptotic signaling pathway GO:0097191 9.77 SMAD3 TGFB1 TGFB2
18 response to progesterone GO:0032570 9.76 TGFB1 TGFB2 TGFB3
19 positive regulation of protein secretion GO:0050714 9.75 TGFB1 TGFB2 TGFB3
20 positive regulation of bone mineralization GO:0030501 9.74 SMAD3 TGFB1 TGFB3
21 epithelial to mesenchymal transition GO:0001837 9.73 TGFB1 TGFB2
22 negative regulation of T cell proliferation GO:0042130 9.73 PDE5A TGFB1
23 negative regulation of protein catabolic process GO:0042177 9.73 NOS2 SMAD3
24 SMAD protein signal transduction GO:0060395 9.73 SMAD3 TGFB1 TGFB2 TGFB3
25 digestive tract development GO:0048565 9.72 TGFB1 TGFB3
26 ventricular septum morphogenesis GO:0060412 9.72 SMAD7 TGFB2
27 mammary gland development GO:0030879 9.72 TGFB1 TGFB3
28 odontogenesis GO:0042476 9.72 TGFB2 TGFB3
29 negative regulation of mitotic cell cycle GO:0045930 9.72 SMAD3 TGFB1
30 face morphogenesis GO:0060325 9.71 TGFB1 TGFB3
31 endoderm development GO:0007492 9.71 SMAD3 TGFB1
32 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.7 SMAD7 TGFB1
33 positive regulation of collagen biosynthetic process GO:0032967 9.7 TGFB1 TGFB3
34 positive regulation of pri-miRNA transcription from RNA polymerase II promoter GO:1902895 9.7 SMAD3 TGFB1
35 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.7 SMAD3 SMAD7 TGFB1
36 negative regulation of DNA replication GO:0008156 9.69 TGFB1 TGFB3
37 negative regulation of immune response GO:0050777 9.68 TGFB1 TGFB2
38 lens fiber cell differentiation GO:0070306 9.68 SMAD3 TGFB1
39 positive regulation of SMAD protein import into nucleus GO:0060391 9.67 TGFB1 TGFB3
40 SMAD protein complex assembly GO:0007183 9.67 SMAD3 TGFB1
41 SMAD protein import into nucleus GO:0007184 9.67 TGFB1 TGFB2
42 pathway-restricted SMAD protein phosphorylation GO:0060389 9.67 SMAD7 TGFB1 TGFB2
43 heart valve morphogenesis GO:0003179 9.66 TGFB1 TGFB2
44 regulation of striated muscle tissue development GO:0016202 9.66 SMAD3 TGFB1
45 regulation of binding GO:0051098 9.64 SMAD3 TGFB1
46 positive regulation of extracellular matrix assembly GO:1901203 9.64 SMAD3 TGFB1
47 regulation of transforming growth factor beta2 production GO:0032909 9.63 SMAD3 TGFB2
48 frontal suture morphogenesis GO:0060364 9.63 TGFB1 TGFB3
49 salivary gland morphogenesis GO:0007435 9.63 TGFB1 TGFB2 TGFB3
50 ossification involved in bone remodeling GO:0043932 9.62 TGFB1 TGFB3

Molecular functions related to Peyronie's Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.73 SMAD3 TGFB1 TGFB2 TGFB3
2 cytokine activity GO:0005125 9.62 IFNA2 TGFB1 TGFB2 TGFB3
3 growth factor activity GO:0008083 9.58 TGFB1 TGFB2 TGFB3
4 collagen binding GO:0005518 9.54 DCN SMAD3 SMAD7
5 type I transforming growth factor beta receptor binding GO:0034713 9.43 SMAD7 TGFB1 TGFB3
6 type II transforming growth factor beta receptor binding GO:0005114 9.33 TGFB1 TGFB2 TGFB3
7 transforming growth factor beta receptor binding GO:0005160 9.26 SMAD3 TGFB1 TGFB2 TGFB3
8 type III transforming growth factor beta receptor binding GO:0034714 8.8 TGFB1 TGFB2 TGFB3

Sources for Peyronie's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....